Abbott Laboratories (NYSE: ABT), one of today's most diversified health care companies, is set to spin off its pharmaceutical division into a new company called AbbVie. AbbVie's biggest asset will be Humira, a blockbuster drug used primarily for the treatment of rheumatoid arthritis. AbbVie, however, won't be without risks as Humira's patent expires in 2016, and rival drugs start entering the market.

In this video, health care analysts Max Macaluso and Brenton Flynn discuss how Abbott is set to change at the start of next year because of this spin-out and several topics investors need to watch in the coming months.

Editor's note: At 2:00, Max meant to say "ulcerative colitis and pediatric Crohn's disease."

link

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.